Linked Life Data

18534575

Source:http://linkedlifedata.com/resource/pubmed/id/18534575

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-3
pubmed:dateCreated
2008-7-28
pubmed:abstractText
A recent clinical study has shown that carvedilol has a significantly more favorable effect than metoprolol on survival rate in patients with heart failure. This may be due to actions of carvedilol such as beta(2)-adrenoceptor blockade, alpha-adrenergic receptor blockade and other properties such as anti-oxidant effects that are not yet fully understood. We compared the effects of racemic carvedilol, metoprolol and carvedilol enantiomers on cardiac hypertrophy at similar heart rate in rats with isoproterenol-induced cardiac hypertrophy. Continuous administration of isoproterenol for 2 weeks produced heart failure, which is characterized by an increased heart rate, cardiac hypertrophy and downregulation of beta-adrenoceptors. The doses of racemic carvedilol and metoprolol were adjusted to obtain a similar heart rate in rats with isoproterenol-induced cardiac hypertrophy. The reduction of left ventricular weight and improvement of cAMP production induced by carvedilol were superior to those induced by metoprolol. Although heart rate, blood pressure and cAMP production were not affected by R-carvedilol, left ventricular weight was significantly reduced as a result of alpha-adrenoceptor blockade. The improvement of cAMP production by S-carvedilol was significantly higher than that induced by coadministration of R-carvedilol and metoprolol, suggesting that beta(2)-adrenoceptor blockade partly contributed to the improvement of signal transduction in rats with isoproterenol-induced cardiac hypertrophy. This study has demonstrated that the effects of carvedilol on cAMP production and cardiac hypertrophy in rats with isoproterenol-induced cardiac hypertrophy are superior to those induced by metoprolol at a similar heart rate.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0014-2999
pubmed:author
pubmed:issnType
Print
pubmed:day
28
pubmed:volume
589
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
194-200
pubmed:meshHeading
pubmed-meshheading:18534575-Adenylate Cyclase, pubmed-meshheading:18534575-Adrenergic alpha-Antagonists, pubmed-meshheading:18534575-Adrenergic beta-Antagonists, pubmed-meshheading:18534575-Animals, pubmed-meshheading:18534575-Blood Pressure, pubmed-meshheading:18534575-Carbazoles, pubmed-meshheading:18534575-Cardiomegaly, pubmed-meshheading:18534575-Cyclic AMP, pubmed-meshheading:18534575-Disease Models, Animal, pubmed-meshheading:18534575-Heart Failure, pubmed-meshheading:18534575-Heart Rate, pubmed-meshheading:18534575-Isoproterenol, pubmed-meshheading:18534575-Male, pubmed-meshheading:18534575-Metoprolol, pubmed-meshheading:18534575-Myocardium, pubmed-meshheading:18534575-Propanolamines, pubmed-meshheading:18534575-Rats, pubmed-meshheading:18534575-Rats, Wistar, pubmed-meshheading:18534575-Receptors, Adrenergic, beta, pubmed-meshheading:18534575-Time Factors, pubmed-meshheading:18534575-Ventricular Function, Left
pubmed:year
2008
pubmed:articleTitle
Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers.
pubmed:affiliation
Department of Biopharmaceutics, Meiji Pharmaceutical University, Tokyo, Japan. hanada@my-pharm.ac.jp <hanada@my-pharm.ac.jp>
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't